We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
-1.68%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.43B
AUM Growth
+$172M
Cap. Flow
+$215M
Cap. Flow %
15.04%
Top 10 Hldgs %
3.57%
Holding
2,136
New
582
Increased
568
Reduced
423
Closed
559

Top Sells

Rank Stock Value
1
JBSS icon
John B. Sanfilippo & Son
JBSS
+$3.41M
2
APA icon
APA Corp
APA
+$3.31M
3
ZTS icon
Zoetis
ZTS
+$3.2M
4
UGI icon
UGI
UGI
+$3.03M
5
DOCU
DocuSign
DOCU
+$2.87M

Sector Composition

Rank Sector Weight
1 Technology 15.39%
2 Healthcare 13.4%
3 Consumer Discretionary 13.25%
4 Financials 12.49%
5 Industrials 11.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LXP icon
951
LXP Industrial Trust
LXP
$3.57B
$511K 0.04%
11,207
+3,063
+38% +$134K
CNTA
952
DELISTED
Centessa Pharmaceuticals
CNTA
$509K 0.04%
56,383
+42,796
+315% +$406K
DXCM icon
953
DexCom
DXCM
$32B
$508K 0.04%
4,481
-1,650
-27% -$209K
CCB icon
954
Coastal Financial
CCB
$693M
$507K 0.04%
+10,993
New +$462K
CSIQ icon
955
Canadian Solar
CSIQ
$1.08B
$507K 0.04%
34,396
-15,670
-31% -$265K
EMBC icon
956
Embecta
EMBC
$262M
$507K 0.04%
+40,536
New +$492K
FIVE icon
957
Five Below
FIVE
$13.5B
$507K 0.04%
+4,649
New +$644K
AIA icon
958
iShares Asia 50 ETF
AIA
$4.73B
$505K 0.04%
7,522
+1,911
+34% +$123K
CHX
959
DELISTED
ChampionX
CHX
$505K 0.04%
15,207
+6,502
+75% +$222K
FOLD
960
DELISTED
Amicus Therapeutics
FOLD
$503K 0.04%
+50,719
New +$521K
NVEE
961
DELISTED
NV5 Global
NVEE
$503K 0.04%
+21,648
New +$505K
ATYR
962
aTyr Pharma
ATYR
$50.1M
$503K 0.04%
322,460
+98,313
+44% +$171K
SPRY icon
963
ARS Pharmaceuticals
SPRY
$612M
$502K 0.04%
58,979
-69,910
-54% -$620K
ZION icon
964
Zions Bancorporation
ZION
$10.3B
$502K 0.04%
+11,572
New +$488K
LGND icon
965
Ligand Pharmaceuticals
LGND
$6.36B
$500K 0.04%
5,939
+1,419
+31% +$113K
PSNL icon
966
Personalis
PSNL
$1.51B
$499K 0.03%
426,876
+6,735
+2% +$9.24K
SNDL icon
967
Sundial Growers
SNDL
$320M
$499K 0.03%
262,893
+103,355
+65% +$221K
NECB icon
968
Northeast Community Bancorp
NECB
$367M
$497K 0.03%
27,917
-809
-3% -$13.3K
FTNT icon
969
Fortinet
FTNT
$117B
$496K 0.03%
8,230
-93
-1% -$5.78K
FRST icon
970
Primis Financial Corp
FRST
$404M
$495K 0.03%
47,244
+30,299
+179% +$317K
LRCX icon
971
Lam Research
LRCX
$390B
$495K 0.03%
4,650
+2,260
+95% +$217K
MTH icon
972
Meritage Homes
MTH
$4.86B
$495K 0.03%
+6,112
New +$514K
RGA icon
973
Reinsurance Group of America
RGA
$16.1B
$494K 0.03%
2,407
-259
-10% -$51.7K
BRSL
974
Brightstar Lottery PLC
BRSL
$2.03B
$493K 0.03%
+24,101
New +$493K
NVR icon
975
NVR
NVR
$17B
$493K 0.03%
+65
New +$497K

Similar funds

GSA Capital Partners's Q2 2024 Portfolio in Review

As of Q2 2024, GSA Capital Partners held 2,136 positions worth $1.43B, up 14% from $1.26B the previous quarter. Its ten largest holdings account for 3.6% of the portfolio.

GSA Capital Partners deployed $215M of net new capital in Q2 2024, opening 582 new positions and adding to 568 existing holdings. Its largest new stake was Genuine Parts: 28,253 shares worth $3.91M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was UGI, an estimated $3.03M trimmed.

  • GSA Capital Partners's largest Q2 2024 buy was Genuine Parts: 28,253 shares worth $3.91M.
  • GSA Capital Partners added most to Devon Energy in Q2 2024, an estimated $5.97M increase.
  • GSA Capital Partners's biggest Q2 2024 reduction was UGI, cutting an estimated $3.03M.
  • GSA Capital Partners fully exited John B. Sanfilippo & Son in Q2 2024, selling an estimated $3.41M.
  • GSA Capital Partners's ten largest holdings make up 3.6% of its $1.43B portfolio in Q2 2024.
  • GSA Capital Partners opened 582 new positions and closed 559 in Q2 2024.
  • GSA Capital Partners's portfolio value rose 14% quarter-over-quarter to $1.43B.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.